Carlsson 2018 - body-weight exposure covariate
Semaglutide is a GLP-1 agonist, Tirzepatide is a dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) agonist, and Retatrutide is a triple GLP-1/GIP/glucagon agonist
Seek urgent medical attention (contact 111 or attend A&E) if you develop: Severe, sudden-onset headache ("thunderclap" pattern) unlike any previous headache Headache with fever, rash, or altered consciousness Persistent vomiting preventing fluid intake or medicine absorption Visual changes including double vision, blind spots, or temporary vision loss Signs of severe dehydration (dark urine, dizziness on standing, reduced urination) Symptoms suggesting pancreatitis (severe upper abdominal pain radiating to the back) Symptoms suggesting gallbladder problems (right upper abdominal pain, fever, yellowing of skin/eyes) Your healthcare provider needs to assess whether headaches represent a straightforward medicine side effect or indicate a more complex issue
To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data
